On May 15, 2025, B. Riley Securities analyst Yuan Zhi maintained their 'Buy' rating for Hyperfine (HYPR, Financial). Despite retaining the 'Buy' recommendation, the analyst has adjusted the price target downward.
The price target for Hyperfine (HYPR, Financial) has been lowered from USD 1.20 to USD 1.00, marking a 16.67% decrease. This price target adjustment reflects a reassessment of the stock's market potential while maintaining a positive outlook on the company's performance.
Hyperfine (HYPR, Financial), listed on NASDAQ, continues to garner attention due to its innovative contributions to the medical technology sector. The company remains under close watch by investors and analysts as it navigates future market conditions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Hyperfine Inc (HYPR, Financial) is $0.98 with a high estimate of $1.50 and a low estimate of $0.68. The average target implies an upside of 64.02% from the current price of $0.60. More detailed estimate data can be found on the Hyperfine Inc (HYPR) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Hyperfine Inc's (HYPR, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Hyperfine Inc (HYPR, Financial) in one year is $2.54, suggesting a upside of 324.04% from the current price of $0.599. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Hyperfine Inc (HYPR) Summary page.
